Patents by Inventor Xiaoxia Zheng
Xiaoxia Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250066199Abstract: A carbonaceous material contains element O, where the content of element O of the carbonaceous material tested by X-ray photoelectron spectroscopy is denoted as A, the content of element O of the carbonaceous material tested by elemental analysis is denoted as B, and the carbonaceous material satisfies A/B?3 and 5 wt %?A?20 wt %.Type: ApplicationFiled: November 13, 2024Publication date: February 27, 2025Inventors: Xiaoxia CHEN, Yu MA, Xinxin ZHANG, Chuying OUYANG, Xiaoji ZHENG, Shangdong CHEN, Wenguang LIN
-
Publication number: 20250059044Abstract: A carbonaceous material where in the CO2 adsorption test of the carbonaceous material, the total CO2 adsorption at 0° C. and a relative pressure P/P0 between 10?8 and 0.029 is recorded as A, the adsorption time is recorded as B, and the carbonaceous material satisfies: A/B?1.7 cm3/(g×h) STP, where STP is the standard condition, P represents the test pressure of CO2, and P0 represents the saturated vapor pressure of CO2 at 0° C.Type: ApplicationFiled: October 31, 2024Publication date: February 20, 2025Inventors: Xiaoxia CHEN, Xinxin ZHANG, Chuying OUYANG, Yu MA, Xiaolong LI, Xiaoji ZHENG, Wenguang LIN, Shangdong CHEN
-
Publication number: 20250059045Abstract: A carbonaceous material has an adsorption velocity v that satisfies 0.015?v?0.050 when subjected to an adsorption test using water vapor at a constant temperature and humidity of 25° C. and 40% RH. The water vapor adsorption test is performed under the following conditions: in a constant temperature and humidity chamber at 25° C. and 40% RH, the carbonaceous material with a mass of m1 is placed in a container, and a water vapor adsorption mass m2 and a water vapor adsorption time t are recorded when the water vapor adsorption of the carbonaceous material reaches equilibrium, and the water vapor adsorption velocity is v=m2/(m1×t), where mi is measured in g, m2 is measured in g, and t is measured in h.Type: ApplicationFiled: November 8, 2024Publication date: February 20, 2025Inventors: Yu MA, Xinxin ZHANG, Xiaoxia CHEN, Chuying OUYANG, Wenguang LIN, Shangdong CHEN, Weiming CHENG, Xiaoji ZHENG
-
Patent number: 12207274Abstract: Methods, systems, and devices for signaling for transmission configuration indication (TCI) state activation for multiple transmission reception points are described. A user equipment (UE) may receive at least one control message indicating a first set of beam configurations associated with a first downlink shared channel from a first transmission reception point (TRP) and a second set of beam configurations associated with a second downlink shared channel from a second TRP. The UE may receive downlink control information (DCI) from the first and second TRPs indicating a first beam configuration of the first set of beam configurations and a second beam configuration of the second set of beam configurations, respectively. The UE may subsequently decode a first downlink transmission from the first downlink shared channel according to the first beam configuration and a second downlink transmission from the second downlink shared channel according to the second beam configuration.Type: GrantFiled: January 13, 2021Date of Patent: January 21, 2025Assignee: QUALCOMM IncorporatedInventors: Ruiming Zheng, Mostafa Khoshnevisan, Linhai He, Xiaoxia Zhang
-
Publication number: 20240424175Abstract: Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including at least one of a chelating agent, a direct factor Xa inhibitor, a direct factor IIa inhibitor, and a factor XI/XIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent a target site in the patient's body. The therapeutic composition is formulated to release the one or more active substances to the target site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation. Delayed or other controlled release of the therapeutic composition from the structure may be provided.Type: ApplicationFiled: May 23, 2024Publication date: December 26, 2024Applicant: Elixir Medical CorporationInventors: John YAN, Xiaoxia ZHENG, Vinayak D. BHAT, Motasim SIRHAN
-
Publication number: 20240074882Abstract: The disclosure provides biodegradable implantable devices such as a stent comprising a biodegradable polymeric material wherein the polymeric material is treated to control crystallinity and/or Tg. The stent is capable of expanding at body temperature in a body lumen from a crimped configuration to a deployed diameter and will have sufficient strength to support a body lumen when expanded.Type: ApplicationFiled: March 30, 2022Publication date: March 7, 2024Applicant: Elixir Medical CorporationInventors: Xiaoxia Zheng, John Yan, Vinayak Bhat
-
Publication number: 20230293540Abstract: Devices, formulations, compositions, and methods are provided for inhibiting an inflammatory ophthalmic disease or eye condition in a patient. A therapeutic composition comprising a direct factor Xa inhibitor and/or a direct factor II inhibitor is provided. A therapeutically effective dose of the therapeutic composition is delivered to a site of the inflammatory ophthalmic disease or condition in the patient’s eye(s). The therapeutic composition may be formulated for delivery to the patient by via injection, an implant, an eye drop, an emulsion, a suspension, an ointment, a nanomicelle, a nanoparticle, a nanosuspension, a liposome, an in-situ gel, a contact lens, or a microneedle or the like. The therapeutic composition may include one or more additional therapeutically active substances and/or one or more additional pharmaceutical agents.Type: ApplicationFiled: March 6, 2023Publication date: September 21, 2023Applicant: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat, Motasim Sirhan, Margaret Wong, Blaine Bueche
-
Publication number: 20230190499Abstract: Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation.Type: ApplicationFiled: February 6, 2023Publication date: June 22, 2023Applicant: Elixir Medical CorporationInventors: Motasim Sirhan, Xiaoxia Zheng, Vinayak D. Bhat, John Yan
-
Publication number: 20230165874Abstract: Devices, compositions, and methods are provided for inhibiting an inflammatory, fibrotic, and/or clot formation for pulmonary disease or condition in a patient. A therapeutic composition comprising a direct factor Xa inhibitor and/or a direct factor IIa inhibitor is provided. A therapeutically effective dose of the therapeutic composition is delivered to a site of the inflammatory, fibrotic, and/or clot formation pulmonary disease or condition in the patient's lung(s). The therapeutic composition may be formulated for delivery to the patient by inhalation, ventilation, instillation, ultrasound, vibration, injection, or the like. The therapeutic composition may include one or more additional therapeutically active substances and/or one or more additional pharmaceutical agents.Type: ApplicationFiled: January 27, 2023Publication date: June 1, 2023Applicant: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat, Motasim Sirhan, Blaine Bueche
-
Publication number: 20230165839Abstract: The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.Type: ApplicationFiled: September 9, 2022Publication date: June 1, 2023Applicant: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
-
Patent number: 11654036Abstract: Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation.Type: GrantFiled: August 13, 2021Date of Patent: May 23, 2023Assignee: Elixir Medical CorporationInventors: Motasim Sirhan, Xiaoxia Zheng, Vinayak D. Bhat, John Yan
-
Publication number: 20220039976Abstract: Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation.Type: ApplicationFiled: August 13, 2021Publication date: February 10, 2022Applicant: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat, Motasim Sirhan
-
Publication number: 20210008040Abstract: The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, —OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.Type: ApplicationFiled: May 20, 2020Publication date: January 14, 2021Applicant: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
-
Patent number: 10695327Abstract: A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, isomers, or N-oxides thereof.Type: GrantFiled: October 8, 2018Date of Patent: June 30, 2020Assignee: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
-
Publication number: 20200093619Abstract: The disclosure provides biodegradable implantable devices such as a stent comprising a biodegradable polymeric wherein the polymeric material is treated to control crystallinity and/or Tg. The stent is capable to expand at body temperature in a body lumen from a crimped configuration to a deployed diameter and have sufficient strength to support a body lumen.Type: ApplicationFiled: February 20, 2018Publication date: March 26, 2020Applicant: Elixir Medical CorporationInventors: Xiaoxia Zheng, John Yan, Vinayak Bhat
-
Publication number: 20190275013Abstract: The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.Type: ApplicationFiled: October 8, 2018Publication date: September 12, 2019Applicant: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
-
Patent number: 10123996Abstract: A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, isomers, or N-oxides thereof.Type: GrantFiled: June 13, 2016Date of Patent: November 13, 2018Assignee: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
-
Publication number: 20170156899Abstract: The disclosure provides biodegradable implantable devices such as a stent comprising a biodegradable polymeric wherein the polymeric material is treated to control crystallinity and/or Tg. The stent is capable to expand at body temperature in a body lumen from a crimped configuration to a deployed diameter and have sufficient strength to support a body lumen.Type: ApplicationFiled: January 31, 2017Publication date: June 8, 2017Applicant: Elixir Medical CorporationInventors: Xiaoxia Zheng, John Yan, Vinayak Bhat
-
Publication number: 20170119741Abstract: The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.Type: ApplicationFiled: June 13, 2016Publication date: May 4, 2017Inventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
-
Patent number: 9566371Abstract: The disclosure provides biodegradable implantable devices such as a stent comprising a biodegradable polymeric wherein the polymeric material is treated to control crystallinity and/or Tg. The stent is capable to expand at body temperature in a body lumen from a crimped configuration to a deployed diameter and have sufficient strength to support a body lumen.Type: GrantFiled: July 21, 2015Date of Patent: February 14, 2017Assignee: Elixir Medical CorporationInventors: Xiaoxia Zheng, John Yan, Vinayak Bhat